Compare NEO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEO | NVCR |
|---|---|---|
| Founded | 2001 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2008 | 2015 |
| Metric | NEO | NVCR |
|---|---|---|
| Price | $8.40 | $17.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $13.38 | ★ $28.08 |
| AVG Volume (30 Days) | ★ 2.1M | 1.7M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $655,353,000.00 |
| Revenue This Year | $10.63 | $7.72 |
| Revenue Next Year | $9.73 | $6.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.28 |
| 52 Week Low | $4.72 | $9.82 |
| 52 Week High | $13.74 | $20.05 |
| Indicator | NEO | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 46.83 | 66.39 |
| Support Level | $7.50 | $12.66 |
| Resistance Level | $8.84 | $18.92 |
| Average True Range (ATR) | 0.55 | 1.04 |
| MACD | -0.07 | 0.13 |
| Stochastic Oscillator | 10.44 | 80.98 |
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.